The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1556
ISSUE1556
September 24, 2018
Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
September 24, 2018 (Issue: 1556)
The FDA has approved elagolix (Orilissa – AbbVie),
an oral gonadotropin-releasing hormone (GnRH)
antagonist, for management of moderate to severe
pain associated with endometriosis.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.